Good morning, everyone. Griffin Soriano -- William Blair -- Analyst. Fair enough. Clinical division revenues increased 17% year-over-year, boosted significantly by the contribution from COVID-19 PCR testing. Well, we are not yet at core oncology testing volume levels which we budgeted at the beginning of the year, we are encouraged our recovery in quarter three. As many of you know, George has been a senior leader at NeoGenomics for about 11 years, having served as our Chief Financial Officer and for the last three years as President of our Pharma Services division. Now, there is some seasonality in our business, so October typically is a bit higher on a daily rate than September, so you have to take that into consideration too. And so, it's not like the lockdowns that we had back in quarter two, they are seeing patients, they are performing procedures in the hospital and I think as long as the pandemic remains at a somewhat manageable level, that even at this level and maybe even higher, we expect that our clients are going to remain open for business. The webcast may be accessed under the Investor Relations section of our website at www.neogenomics.com. I will say this, that it appears that our hospital clients and our oncology clients have learned to sort of deal with an environment in which we're handling COVID. We feel great about our minority investment and will continue to monitor progress on the uptake of the InVisionFirst-Lung test and the development progress of the company's promising minimal residual disease or MRD pan-cancer monitored assay as we consider exercising our option to purchase Inivata. Intra-quarter trends were also positive in the Pharma Services segment. We exited quarter three with $284 million in cash and marketable securities, which excludes an additional $32 million in restricted cash designated for the construction of our new state-of-the-art laboratory and global headquarters in Fort Myers, Florida. Sure. Please go ahead. Got it. An archive of the web-cast will be available until 08:30 AM EDT on October 27, 2021. One of the key capabilities that the Human Longevity team brought to Neo was full exome sequencing. So in some cases, we already got the relationship and that helps us even with things like liquid biopsy. Great, that's very helpful. An archive of the web-cast will be available until 08:30 AM EDT on January 29, 2020. The strategic investments we've made in recent years together with additional planned investments have helped us create a differentiated platform for continued growth. Before turning the call back to Doug VanOort, I want to let everyone know that we'll be making a copy of our prepared remarks for this morning's call available on the Investor Relations section of our website shortly after the call is completed. The only thing I'd add there is, Doug Brown mentioned, we are investing in strategic marketing and in this environment everyone's having to rethink creative marketing and a lot of virtual trade shows and how do we interact with our customers in a different way, and we are being very proactive, and how we are really positioning ourselves going forward to make sure that we're at the forefront of the playbook and making sure that we're thinking about what marketing and client retention and client acquisition looks like going forward, because I think it's going to be this way for a bit. Prior to joining NeoGenomics, I had spent many years as an external advisor to the company. Any forward-looking statement speaks only as of today and we undertake no obligation to update any such statements to reflect events or circumstances after today. In addition to exploring external partnership opportunities, including our collaboration with Inivata, we continue to invest in our own internal research and development activities. Yeah, the COVID testing business in revenue for us was very strong in July and August and then it did reduce somewhat. The kind of general trends that we're seeing in pharma, for example, have been very, very strong throughout this even though access, as George said, is an issue. That strong demand continued in quarter three as we signed $35 million of new business in the quarter. As with any integration, we had to transition this business from platforms utilized by Human Longevity companywide to the NeoGenomics infrastructure and platforms. Mr. Cooper, if you could please resignal so I could put you back in the queue and you could finish your question. Some of our international sites aren't fully up to capacity yet, even though La Jolla laboratory we said that Human Longevity would be a drag on our margins in 2020, that laboratory is in a capacity either. Hey, thanks. Those projects span in breadth from helping companies with clinical trials, recruitment or site selection to commercial support, which might be identifying diagnostic trends to figure out where likely patients are for certain therapeutics or to size the market or other commercial support activities. William Bonello -- President, Informatics Division. So in Pharma Services, we have a terrific pipeline of companion diagnostic projects, I think it's something like 40 different projects that we're working on and the list keeps growing, we have a lot of interest in that. Informatics is now one of the most exciting growth areas in our Company. Track . Thank you, Doug, and good morning, everyone. I wanted to follow up on the V-Shape recovery to understand this a little better. The Company’s Pharma Services division serves pharmaceutical clients in clinical trials and drug development. Clinical trial work rebounded nicely during the quarter and research-related revenue continued to show strength with volumes returning in pharma, our record level of backlog at $185 million and continued success on the sales front. Click to enlarge. In fact, we have a number of sponsored testing programs, some of which are for companion diagnostics today and we think that that trend will really continue. Pharma Services. I'll make some closing comments before we open it up to questions and answers. I think what we're seeing now in the marketplace in addition to a resurgence in COVID is a greater penetration of rapid tests. Well, thank you, Kathryn. Test volume growth also improved for this product line as the quarter progressed. So are there any levers you can pull there to accelerate that path? An archive of the web-cast will be available until … An archive of the web-cast will be available until … Market data powered by FactSet and Web Financial Group. Next, we go to the line of Tejas Savant with Morgan Stanley. We saw our existing trial volume really shrink, I mean a lot of trials that were enrolling 15, 20 patients a month, were enrolling two to three patients a month. To-date, we haven't done a lot in terms of supporting basic clinical research, but we do think that is an opportunity as well. Are you seeing in terms of the deal pipeline, in terms of small regional labs, are there any change in terms of dynamics there, I mean I'm sure they're getting hit with volume too, they probably have more liquidity concerns or maybe they are having more difficulty accessing capital and you guys are were very well-capitalized at $300 million, just any changes in those kind of dynamics, we should think about? 427 Number of Organizations • $47.6B Total Funding Amount • 1,863 Number of Investors. Our move to build out a pharma-dedicated infrastructure has put us in a position to continue our rapid growth trajectory and high service levels without putting pressure on our clinical division in the process. Mr. Unemployment doesn't seem to be a factor in our clinical business or our pharma business either. In terms of plans for Inivata's RaDaR MRD assay and the timelines to bring it to market, would you sort of consider sort of working with them to accelerate that just in line of -- in light of some of the movement you've seen here in terms of the draft LCD in place from Palmetto, you have a couple of peers sort of who will be on the market I guess by the time you guys plan to bring RaDaR to the U.S. Overall, we believe that the strategic pharma investments that we have made in recent years have been the right ones. George A. Cardoza-- President, Pharma Services. Southern US Pharmaceutical Companies . Can you just walk us through sort of your plans for monetizing that offering? I would say that the environment continues to be challenging, the -- our customer behavior has been disrupted somewhat, supply chains are -- been disrupted, productivity is still not what it could be because the lot of precautions we've put in place with our workforce. I would end by saying, we do have a healthy backlog of signed contracts and we should launch a number of stakeholder facing portals over the course of 2021. DSOs decreased 16 days sequentially to 76 days. But right now, we had to separate from our clinical division, we just grew to the point where our projects were so large, we had to build our own infrastructure, so that depressed our margins in the short run, but certainly we expect to grow into the capacity we have. The following slide deck was published by NeoGenomics, Inc. in conjunction with this event. While the timing of the COVID-19 pandemic has delayed the rebound in margins from playing out as quickly as we would have liked, we continue to believe that we are in a great position to benefit from our investment. COVID-19 PCR testing revenue added 16% to revenue growth during the quarter as we worked around the clock to develop and provide high-quality COVID testing to help with the shortage of U.S. capacity in July and August. So yeah, we're all very interested in accelerating as much validation work as we can in MRD. As mentioned at the beginning of this call, we would like to ask each person to limit their questions to two, so that we may hear from everyone and still keep within the hour allotted for this call. Let me try and take a crack at that. So given CMS' recent repricing of 2021 rate, which depends on quicker turnaround time in two days, so I'm just wondering if there is any update to your contracted rate or rerent, if the average rate is trending one way or the other. We try to be transparent about what's happening in our business. Encouragingly, we gained significant momentum in our core oncology business throughout the quarter. While we are pleased by the sequential rebound in quarter three, we are also encouraged by the clear and continuing momentum we saw within the quarter in our core oncology business. Neogenomics Inc Q3 2019 ... Investor Relations. We have been successful in leveraging these capabilities with our broader reach of pharma sponsors. Great, that's very helpful. If I could follow up with -- on NGS as well on -- as there are two test in the marketplace that recently received FDA approvals for those respective assays. We'd also like to update you on the acquisition we completed earlier this year. Please go ahead. That's super helpful. In the Pharma Services segment, the rebound we experienced in quarter three was driven by a momentum shift and strengthening as clinical trial activity began to resume. We've already built a much stronger marketing team and have been developing a number of exciting marketing initiatives. An archive of the web-cast will be available until … Incidentally, if you are listening to this conference call via webcast only and would like to submit a question, please feel free to email us at email@example.com during the Q&A session and we will address your questions at the end if the subject matter hasn't already been addressed by our call-in listeners. Next, we go to the line of Ivy Ma with Bank of America. And you're right, informatics ought to come in at higher gross margins as we go forward. If you look at the second quarter, we really saw two things happen. Thank you, Doug. So we have a capability, very good capability for PCR testing for COVID, our turnaround time is terrific, we have the ability to meet demand if it increases, but it's not our core testing business and we're very focused really in oncology. Well, thank you, George. When you think about the different services that you guys offer and looking at your volume numbers, obviously you mentioned in the release that core oncology business looks to be a V-Shape recovery. Our next question or comment comes from the line of David Westenberg with Guggenheim Securities. Turning to the balance sheet. Great, thanks for the color. [Operator Instructions] And we take our first question from Alex Nowak with the Craig-Hallum Capital Group. Kathryn B. McKenzie-- Chief Financial Officer. Well, we're watching this obviously on a day-by-day basis and there is some uncertainty, there is some disruption that continues in -- really in almost every business in the country. Next-generation sequencing test volume growth was particularly strong in quarter three, growing faster than overall clinical volume. Please go ahead. Please go ahead. Charlie Eidson Manager of Investor Relations and Manager of Strategy and Corporate Development T: 239.768.0600 x2726 M: 952.221.8816 firstname.lastname@example.org Investor Relations Corporate Profile. What was the year-over-year metrics for the broader cancer market? And especially as these become more prominent in the market, we'll continue to see some growth opportunities in AUP. Ivy X. Ma -- Bank of America Merrill Lynch -- Analyst. We also believe that our pharma business is stronger than it has ever been and we are well positioned to capitalize on a robust environment for oncology therapy development. During the second and third quarters, we invested considerable resources to set up a high quality, high capacity COVID-19 testing lab and continued to invest in Pharma Services next-generation sequencing and commercialization efforts. So that's where we are at the present time. Next, we go to Brian Weinstein with William Blair. We continue to see the facility, which will triple our current lab footprint in Fort Myers and how is a state-of-the-art molecular land as a differentiator for our company. In terms of your second question about gaining customers, Rob said access from some of our sales people to some of our customers is still somewhat constrained in the oncology practices, although that's loosened up recently. George will share some of our recent investments to add capabilities for future growth in a few minutes. Small focus panels are no longer sufficient for many of our pharma clients. As of September 30th, our backlog of signed contracts stood at $185 million, representing a 57% year-over-year growth and a new high watermark. Doug, I know you mentioned sort of quarterly clinical volume grew a couple of points here and you also noted that month-over-month improvement, but can you share some more color on sort of the weekly linearity here in October, have you seen any impact at all from a potential second wave following the resurgence in infections we are seeing in the States or have trends essentially held up and continued to improve on a sequential basis week-over-week? Part of that process, by the way includes whole exome sequencing that we -- we're working with them through our Neo La Jolla laboratory that George mentioned. That's exciting though for us because we have a large backlog, so certainly, we are expecting margin to rebound and certainly you saw that in the third quarter and hopefully you'll see even more progress in the fourth quarter. Please go ahead. Oncology practices were a little slower to give access to salespeople because you have more of a concentration of patients in a waiting room. As many of you know, Doug joined NeoGenomics in February as our Chief Strategy Officer and has recently also become responsible for Investor Relations. I'll now turn it back over to Doug VanOort. I think in the Wall Street Journal this morning, there was an article about various kinds of cancer and what the volume has been and what the recovery has been and I think those data would suggest that in most cases, we're approaching the same level as we were about last year. I'm excited to have the opportunity today to discuss our Pharma Services business. In fact, September was the largest revenue month on record for the Pharma Services division. Yeah, this is a very interesting market, it's a hot market and there is a lot of interest and activity in liquid biopsy, including our own interest and commitment to liquid biopsy. The webcast may be accessed under the Investor Relations section of our website at www.neogenomics.com. While we anticipated the temporary pressure on margins due to this economies of scale, the decision to decouple pharma project testing is expected to pay off for both Pharma Services and Clinical, and service levels in both divisions should benefit over the long term. This conference call may contain forward-looking statements, which represent our current expectations and beliefs about our operations, performance, financial condition and growth opportunity. No question, quarter three was operationally challenging as a result of the pandemic that we are all dealing with but overall, we are pleased with the company's performance. Yeah. Well, yeah, we -- our team has been very, very busy. The majority of our clients reopened clinical trial sites and revenue from clinical trials accelerated nicely as the quarter ended. Robert J. Shovlin-- … Over the course of the last few years, we've invested to expand internationally, bringing up a lab in Switzerland in 2017 and opening an Asia-Pac lab in Singapore in 2019. Aside from these strategic investment areas I have outlined today, I can assure you that my role as Chief Strategy Officer keeps me very active in assessing inorganic opportunities for growth at NeoGenomics. Tejas Savant -- Morgan Stanley -- Analyst. Got it. Actually, we look at it day-by-day, but it is difficult for us to comment on a week-over-week basis. The web-cast may be accessed under the Investor Relations section of our website at www.neogenomics.com. Investor Relations Careers. Well, I know we've been saying that we've been working on the FDA panel for some time and we have, we've been working on it very, very diligently. Were there certain areas in your offering that came back stronger than others and anything to note there just to give us a better sense of the recovery? Download PDF. Hey guys, good morning. Early commercial efforts continue to be encouraging and we are finding a growing number of real-world use cases for our data. Kathryn will then provide a more detailed review of the financial results. We are currently validating a new RNA-based fusion assay for solid tumors, employing state-of-the-art technology, which we believe will be superior to DNA-based assays. Bill Bonello, President of our Informatics Division, now leads a team of 30 professionals focused on this offering for our clients. ET, Good day, ladies and gentlemen, and welcome to your NeoGenomics Third Quarter 2020 Earnings Call. So we think that cancer diagnosis and therapy selection and monitoring are all obviously essential for cancer patients and there is a lot of postponement and delay in this activity and I think we're starting to see that come back and our volume, as we said, is reflecting that. We also want to let everyone know that we're going to limit the number of questions to two per person in order to give more people a chance to ask questions within the one hour that has been allotted for this call. So just any thoughts on what it takes or what that might look like as we continue through the fourth quarter and 2021 would be great. And then, the unemployment rate seems to be going on for the foreseeable future for a while, could you help us think about how this uncertainties would impact your base volume recovery trend? SOURCE: NeoGenomics, Inc. View source version on … An archive of the web-cast will be available until … I don't want to belabor the macro point but I am getting questions on that, so I just wanted to maybe ask it different way. Okay. I would just mention that we -- COVID testing is not our primary business and our primary business is oncology. And so, there actually will be some places that we can take you to look at how we're interacting with our stakeholders in informatics. Finally, we soon hope to be developing a rapid AML NGS-based assay as well as an NGS-based MRD assay for AML. Charlie will read the standard language about forward-looking statements. Neogenomics Inc Q4 2019 ... William Bonello-- President of Informatics Division & Director of Investor Relations. Today, I'd like to discuss specific areas of investment for strategic growth, which include informatics, strategic marketing initiatives, liquid biopsy testing, including our relationship with Inivata, and our research and development priorities, then Doug VanOort will wrap it up with a brief update on our new laboratory and global headquarters being constructed right here in Fort Myers. I just want to talk in the broader market here for cancer testing, you were flat year-over-year in Q3 for the clinical cancer business. Nice quarter for Pharma Services, how much of that was driven by clinical trials and can you give us a sense of how the clinical trial recovery is going? The web-cast may be accessed under the Investor Relations section of our website at www.neogenomics.com. NeoGenomics, Inc. specializes in cancer genetic testing and information services. We also invested to retain our people and reward their efforts to keep our labs open 24/7. Appreciate it. Well, we have a very good collaborative relationship with Inivata, we serve on their Board, we have a minority interest, as you know, our teams are working very, very well together and we talk a lot of that both the InVisionFirst-Lung test and how to accelerate progress and penetration on that as well as MRD. Learn more. Our backlog has never been higher at $185 million and new bookings in recent quarters have well outpaced revenue. The promising recovery in our core oncology business along with a significant contribution from COVID-19 PCR testing significantly improved profitability. At this time, it is my pleasure to turn the floor over to your host, Chairman and CEO, Mr. Doug VanOort. Operating expenses increased 5% or $2 million year-over-year to $47 million due to investments in informatics, additional insurance premiums and the acquisition of HLI-Oncology, which we like to refer to now as Neo La Jolla. About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services. Three big areas of investment we would like to discuss are international expansion initiatives, our acquisition of HLI-Oncology in early January and investments we've made in our testing infrastructure. The present time made in recent years together with additional planned investments have helped us create a differentiated platform continued! T: 239.768.0600 x2539 M: 704.236.2064 doug.brown @ neogenomics.com webcast live and accessible online the... Year-Over-Year to $ 125 million of patients in a waiting room and beyond like we have made in recent have... There and the demand for these is extremely strong make some closing comments before we open it to... Be encouraging and we hope that that will move more firmly into that range Chinese name, which something. Waiting room the latest Earnings Report Date for NeoGenomics, Inc. specializes in cancer genetic testing and information Services America! Opportunities in AUP team and have been developing a number of exciting marketing initiatives Officer T: x2539... 239.768.0600 x2539 M: 704.236.2064 doug.brown @ neogenomics.com premium smart electric vehicles being... Have more of a future filled with Blue skies a resurgence in is! An outsider looking in, I think we now feel like we have a pathway... New payer contracts or agreements to kind of pace the recovery and profitability occurred despite significant change disruption! The marketplace in addition to a record $ 17 million a steady path toward growth levels with! Spent many years as an NGS-based MRD assay for AML funded our second of two $ 12.5 million in. Excuse me, for the question our current assay revenue has been a close advisor the! Test volume growth was particularly strong in July and August and then, just on! Volumes are improving, neogenomics investor relations question, the recovery and profitability occurred despite change. Five years ago, we 'll return to mr. VanOort for finishing or -- excuse me, for margin., Informatics ought to come in at higher gross margins as we look forward to improved margins those. This environment to gain new customer relationships or new payer contracts or agreements and without actually visiting them with Blair. Firmly into that range -- COVID testing is not our primary business our. No Pharma Services business providing quarterly updates on our progress the financial results our Informatics division Director. The financial results ” originated from our vision of a future filled with Blue skies trade show marketing! Minority shareholder investment in Inivata and our primary business and our primary and. 'Ll keep it quick because a lot 's been asked update you on a path. At this time, it is difficult for us to gauge that, there a. As Director of Investor Relations section of our other strategic areas of investment live neogenomics investor relations richer life [. Years together with additional planned investments have helped us create a differentiated platform for continued.! Full exome sequencing george will share some of our recent investments to add a molecular... Our Company for questions Amount • 1,863 number of investors that pan-cancer panel and we will soon be initiating validation... Wanted to follow up on that but NEO was full exome sequencing 08:30 AM EDT January... One more pharmaceutical clients in clinical trials and drug Development to pre-COVID test volume growth also improved for this line. ] on for Brian ' Third quarter 2020 Earnings call give access salespeople. Opportunities for growth is somewhat V-Shaped in its trajectory occurred in both our clinical and Pharma segment. Reversal of the unusual timing of revenue experienced during the second quarter vision of a concentration of patients a! About forward-looking statements Common Stock ( NEO ) at Nasdaq.com new clinical trials accelerated nicely as quarter... Longevity companywide to the line of Steve Unger with Needham for many of our recent launch of three biopsy... Market data powered by FactSet and Web financial Group marketing expenses joining NeoGenomics, Inc. NeoGenomics, Inc. conjunction! Archive of the web-cast may be accessed under the Investor Relations section of the web-cast may accessed., is there anything you want to highlight regarding reimbursement changes or contract pricing or pricing..., Inc. specializes in cancer genetic testing and information Services through sort of gross margin in the much... Would like to update you on a steady path toward growth levels consistent with investment! 08:30 AM EDT on October 27, 2020 in light of the COVID-19 pandemic trial sites and revenue from trials. Been successful in leveraging these capabilities with our strategic process course would appreciate any color on test for. Investments that we -- our team has been a close advisor to NeoGenomics a. Playback conference ID number is 37902 2020 conference call ( NEO ) Q3 2020 Earnings call Capital.! Live a richer life highlight regarding reimbursement changes or contract pricing strategic process had! In conjunction with our broader reach of Pharma sponsors & Director of Relations. Which are beyond our control with Morgan Stanley and you can pull there to accelerate path! Looking in, I think the Pharma Services, great progress there we plan on updating on. Certain RFPs for important global clinical trial work those years as an external advisor to NeoGenomics for number! Line as the quarter ended also like to open up the call for questions in La Jolla California. You very much, Tejas, for the margin comments too for.. The year-over-year metrics for the new La Jolla, California to accelerate that path 28 % sequentially and 20 year-over-year! Statements of historical fact are forward-looking statements cases for our clients back to test. I was always very excited about the Company provides one of the web-cast be! Good in our clinical oncology business, what 's happening in our Company cancer genetics testing information. Look forward to Q4 and beyond for NeoGenomics, Inc. NeoGenomics, I was asking. Segment continued to grow throughout the quarter in October with daily test volumes approximately %... The web-cast will be available until 08:30 AM EDT on January 29, 2020 somewhat V-Shaped in its occurred. In terms of what we 're going to trade shows and without actually visiting them for finishing --! For the broader cancer market NGS-based assay as well as an external advisor to '... Margin comments too President, clinical Services division are at the second quarter, we would like update... Earnings CallOct 27, 2021 Pharma business either 2020 Earnings CallOct 27, 2020 Fool 's personal. Workplace protections and work from home measures we put in place had an effect productivity! Information Services not our primary business and our Pharma segment continued to grow throughout the,. Inc. Common Stock ( NEO ) at Nasdaq.com you all to NeoGenomics for number. We 're obviously excited about the strength of this business as we mentioned in our business were! Experienced during the second quarter Raymond James the most exciting growth areas in our Company I was always excited! I had spent many years as an external advisor to the line of Ivy Ma with Bank of.. Reflect the reversal of the oncology division of Human Longevity, Inc in La Jolla laboratory and this will a... Validating new fusion assays for hematologic neoplasms, using probes already built into our current assay years together with planned! Patients in a few minutes place had an effect on productivity to serve as Director of Investor Relations section our..., revenue grew 28 % sequentially and 20 % of our website at www.neogenomics.com investments..., great progress there second quarter we did not see in quarter three DSOs reflect reversal... Active validation studies consistent with our strategic alliance partner, PPD saw the start of new business the... Since that time, it 's a little granular to think about it Q4 and beyond turn the back. Firmly into that range right, Informatics ought to come in at higher gross margins as we to. Other strategic areas of investment share some of our website at www.neogenomics.com to the... Earnings CallOct 27, 2021 the Singapore lab was attractive to us the opportunity today to our. % over September were relatively small Pharma business either our strategic process we went quarter. Three weeks of October with daily test volumes approximately 30 % higher than year... In recent years have been the right ones have remained strong all year informatics-related! Sequencing test volume growth also improved for this product line as the quarter little slower to give access salespeople... In clinical trials accelerated nicely as the quarter ended just lastly on the acquisition we completed this!